NCT07348432 The diabEAT Study: Insulin dElivery Technologies And eaTing Behaviours in People With Type 1 Diabetes
| NCT ID | NCT07348432 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McGill University |
| Condition | Insulin Dependent Diabetes Mellitus |
| Study Type | OBSERVATIONAL |
| Enrollment | 106 participants |
| Start Date | 2024-07-29 |
| Primary Completion | 2026-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 106 participants in total. It began in 2024-07-29 with a primary completion date of 2026-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Type 1 diabetes is an autoimmune health condition that requires daily injections of insulin. Insulin allows the body to use energy from carbohydrates in food. Disordered eating behaviours, like restricting food intake to lose body weight, are more common in women and people with type 1 diabetes, compared to those without because they must practice carbohydrate counting. Carbohydrate counting means identifying, measuring, and planning carbohydrate intake to match insulin dosage. New technologies, such as automated insulin delivery (AID) systems adjust insulin delivery in a blood sugar responsive manner. AID is rapidly replacing conventional insulin delivery like injections or non-automated insulin pumps since it reduces management burden and improves blood sugar levels. It is not known if AID reduces food management and disordered eating behaviours. This study aims to: 1. investigate the relationship between AID and eating behaviours according to gender for youth (12 to 17 years), and adults (18 years and older). 2. Determine the limit of carbohydrate counting inaccuracy to maintain stable blood sugar levels according to insulin delivery method (AID, injections, or pumps). It is hypothesized that those who use AID will have lower disordered eating behaviours and will maintain stable blood sugar levels while allowing for higher carbohydrate counting inaccuracy. This will be a cross-sectional cohort study of people with type 1 diabetes who are 12 years of age or over. Participants will be recruited through the BETTER registry and social medias across Canada. This research is needed to improve nutrition guidelines for type 1 diabetes in the context of new technologies like AID. Evidence from this study may reduce food management burden, lower the risk of disordered eating behaviours, and prevent eating disorders and medical complications.
Eligibility Criteria
Inclusion Criteria: * 12 years of age or older * Living in Canada * Living with type 1 diabetes for more than 1 year * Using at least 2 insulin injections per day or using an insulin pump * Using current insulin delivery system for 3 months or more Exclusion Criteria: * Are pregnant or currently are breastfeeding * Don't speak French or English * Does not have a smart phone (to download applications)
Contact & Investigator
Anne-Sophie Brazeau, PhD
PRINCIPAL INVESTIGATOR
McGill University
Frequently Asked Questions
Who can join the NCT07348432 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Insulin Dependent Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07348432 currently recruiting?
Yes, NCT07348432 is actively recruiting participants. Contact the research team at courtney.south@mail.mcgill.ca for enrollment information.
Where is the NCT07348432 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT07348432 clinical trial?
NCT07348432 is sponsored by McGill University. The principal investigator is Anne-Sophie Brazeau, PhD at McGill University. The trial plans to enroll 106 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.